About Us

Neurodegenerative diseases (NDDs), such as Alzheimer's (AD) and Parkinson's (PD), are among the leading causes of lost years of healthy life and exert a great strain on public healthcare systems. Despite being first described more than a century ago, no effective cure exists for AD or PD. Although extensively characterised at the molecular level, traditional neurodegeneration research remains marred by narrow-sense approaches surrounding amyloid β (Aβ), tau, and α-synuclein (α-syn). NDDs, including AD and PD, are the leading cause of disability-adjusted life years, or lost years of healthy life, accounting for 250.7 million DALYs, or 10.2% of all DALYs, worldwide in 2015. They are also the second-leading cause group of death, with 9.4 million, or 16.8% of global deaths in the same year. Through our systems biology approach, we aim to transform these insights into breakthrough therapeutics that can significantly improve patient outcomes.

Cancer represents a complex metabolic disease where abnormal cellular metabolism drives tumor growth and progression. Our research leverages advanced network analysis to identify cancer-specific metabolic features that serve as potential therapeutic targets. By studying the distinct metabolic profiles of different cancer types, we can develop targeted therapies that address the unique molecular characteristics of each cancer subtype. This systems-level analysis enables us to identify novel drug targets and develop more effective treatment strategies for various cancers, including those with high mortality rates like pancreatic and brain cancers, as well as more common malignancies such as breast, lung, and prostate cancer. Through our systems biology approach, we aim to transform these insights into breakthrough therapeutics that can significantly improve patient outcomes.

Inflammatory disorders are driven by complex immune and metabolic dysregulation, leading to chronic inflammation and tissue damage. Despite advances in understanding individual pathways, effective treatments remain limited due to the multifactorial nature of these diseases. By applying systems biology and causal AI, we analyze the intricate networks of inflammatory mediators and metabolic interactions to uncover novel therapeutic targets. Our approach enables the development of more precise and effective therapies that improve patient outcomes where current options fall short.

Metabolic disorders, such as muscle sarcopenia, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH), are growing public health concerns driven by lifestyle, aging, and systemic metabolic dysfunction. These conditions often co-occur with obesity, insulin resistance, and chronic inflammation, contributing to increased morbidity and mortality. Despite their prevalence, current treatment options remain limited and largely symptomatic. Through our systems biology and network-based analysis, we investigate the underlying molecular mechanisms governing metabolic dysregulation and tissue remodeling. By integrating multi-omics data and causal inference, we aim to uncover actionable targets and design precision therapeutics that can halt or reverse disease progression and restore metabolic homeostasis.